… that veliparib … phase III trial of veliparib is underway comparing carboplatin and
paclitaxel given in combination with placebo versus veliparib in patients with advanced-stage …

… nor in our phase I study 23 , and the benefit of addition of veliparib to cytotoxic chemotherapy
has thus far mainly been shown in preclinical models. The effect of veliparib on the repair …

… veliparib, an oral PARP-1/2 inhibitor, and TMZ result in synergistic tumor growth delay or
regression. We hypothesized that adding veliparib … or 2 prior regimens were randomized 1:1 to …

… In another Phase I study, veliparib was active in patients with … A dose-escalation Phase I
study of veliparib bid on days 1–7 … of veliparib as 40 mg bid A Phase II trial with veliparib and …

… in relapsed SCLC in a phase I trial. We showed the combination of veliparib with platinum
doublet of cisplatin and etoposide (CE) to be safe and tolerable in a phase I trial. The current …

… S1416 compared the efficacy of cisplatin plus PARPi veliparib (Vel) or placebo (P) in 3 groups
of MBC: gBRCA+; BRCA-like; and non-BRCA-like. Methods: Patients (pts) with metastatic …

… Here, we report results from the Phase 2 part of the study that evaluated veliparib or
placebo in combination with carboplatin and etoposide followed by veliparib or placebo …

… with either placebo, veliparib 200 mg, or veliparib 400 mg. The … QTcF between the veliparib
400 mg dose and placebo (∆∆… ∆∆QTcF between veliparib 400 mg and placebo was below the …

… /m 2 , day 1) combined with either veliparib or matching placebo (300 mg orally twice a day,
… who received at least one dose of veliparib or placebo. The study is ongoing and registered …

… recently reported randomized phase II trial of gemcitabine + cisplatin ± veliparib in patients
… study, and would address an important concern (the placebo control arm) of the POLO trial. …